GLP-1 Analogues Market

GLP-1 Analogues Market Size, Share & Trends

The size of global GLP-1 analogues market in terms of revenue was estimated to be worth $47.4 billion in 2024 and is poised to reach $471.1 billion by 2032, growing at a CAGR of 33.2% from 2024 to 2032. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

GLP-1 analogue drugs have gained high acceptance in recent years, especially after their benefits in treating chronic obesity and weight management became known widely. In addition, the clinical pipeline for this drug class is strong. The pipeline reveals an abundance of products (existing and innovative molecules) expected to launch during the forecast period. A few notable product instances include- Oral semaglutide (25 mg and 50 mg) for type 2 diabetes, CagriSema (a combination product of Cagrilintide and Semaglutide) for obesity as well as type 2 diabetes, Survodutide for the treatment of obesity and Nonalcoholic steatohepatitis (NASH), Semaglutide against NASH, and among others. Thus, this is a key factor driving market growth. However, more than 90% of the marketed products are offered by two key players in the market- Novo Nordisk A/S and Eli Lilly and Company. This has created a duopoly in the market. This factor thus, is expected to create high entry barriers for new entrants in the market.

GLP-1 Analogues Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

GLP-1 Analogues Market Dynamics

Driver: Strong R&D pipeline

GLP-1 analogues is a class of drugs referred to as incretin mimetics. These drugs aid in regulating blood glucose levels and promote satiety thus, used in the treatment of diabetes and obesity. The drugs have been in high demand for treating obesity in recent years. Also, the drug class is highly adopted for the treatment of type 2 diabetes. Therefore, many key players are in the development of novel drugs for this class. The clinical pipeline reflects a wide range of products in development, along with existing products being tested for novel indications such as Nonalcoholic Steatohhepatitis (NASH) and Alzheimer’s disease, among others. The R&D pipeline is dominated by Novo Nordisk A/S which is the leading player in this market along with some other large pharmaceutical and biopharmaceutical companies like Boehringer Ingelheim International GmbH (Survodutide), Eli Lilly and Company (Retatrutide, Orforglipron), Innovent (IBI362/Mazdutide), Hanmi Pharm (partnered with Merck; Efinopegdutide), Zealand Pharma A/S (Dapiglutide), and Pfizer, Inc. (Danuglipron), among others. Some of the key products of focus include combination products like CagriSema (combination of Cagrilintide and semaglutide) and IcoSema (combination of basal insulin icodec and semaglutide), and oral GLP-1 products.

Restraint: High entry barriers due to duopoly

The market is dominated by two players- Novo Nordisk A/S (Denmark) and Eli Lilly and Company (US). These key players form a duopoly in the market for currently marketed GLP-1 analogues. Some of the key attributes of this duopoly include- strong brand recognition of the products, established geographic network through which the companies offer their GLP-1 analogues globally, and developed and established infrastructure that supports supply to meet the high demand for GLP-1 analogue drugs. Moreover, both companies have patented formulations that restrict generic drug makers from entering this space. Additionally, anticipating high demand for this GLP-1 analogues, the companies are further developing novel therapeutics of this drug class and also enhancing existing manufacturing capacity.

Opportunity: Extended therapeutic uses

The GLP-1 analogues have been traditionally used for the treatment of diabetes as they regulate blood glucose level. Additionally, with the observation of features such as providing enhanced satiety and slower gastric emptying, they have also been highly adopted for the treatment of obesity. The GLP-1 analogues drugs class is now being studied for its potential in the treatment of other indications such as NASH (nonalcoholic steatohepatitis), Alzheimer’s disease, Obstructive Sleep Apnea (OSA) and several cardiovascular indications. GLP-1 analogues help manage weight loss which is a key factor in managing NASH. Moreover, they have shown potential neuroprotective effects, and they possess anti-inflammatory properties that aid in mitigating the chronic inflammation associated with Alzheimer’s disease. Such factors are expected to support adoption of GLP-1 analogues for a wide range of indications.

Challenge: Non-adherence to therapy after 12-24 months

The GLP-1 analogues is a drug class that has gained high adoption for the treatment of type 2 diabetes and obesity. Treatment adherence is the patient’s actions aligning with the prescribed therapeutic regimen. Thus, non-adherence refers to stopping medications before the complete treatment duration is passed, irregular consumption of doses, and not consuming medication as directed. Patients on GLP-1 analogues have been observed not adhering to the treatment post 12 months of initiation. For instance, a study of antiobesity GLP-1 drugs- Wegovy and Saxenda, reveals a drop to 32% of patients remaining on treatment by end 12 months since initiation of the treatment for Wegovy. This share is 21% for Saxenda. A few reasons noted for the same include the injectable nature of the majority of products, side effects such as nausea and vomiting, and high prices in developing economies. Disease bias or stigma, supply constraints and access to these medicinecs are few of the key reasons for patients quitting anti-obesity GLP-1s. Thus, the growing development of oral GLP-1 analogues with minimal side effects is expected to reduce the impact of this challenge.

GLP-1 analogues Market Ecosystem

Prominent companies in the market include companies that have been operating for several years and possess a diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in the market include Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), and AstraZeneca (UK), among others.

Ecosystem analysis

The GLP-1 analogues market ecosystem comprises supply-side companies as well as demand-side entities that significantly contribute to market growth. The supply-side ecosystem includes pharmaceutical and biotechnology companies, while demand-side entities include home care settings, long-term care facilities, hospitals, and specialty clinics.

Ozempic accounted for the largest share of the product segment in overall GLP-1 analogues industry in 2023.

On the basis of product, the GLP-1 analogues market is segmented product into Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Xultophy, Soliqua, Zepbound, Bydureon, and other products. In 2023, the Ozempic segment accounted for the largest share of the market owing to factors such as strong brand recognition for the product, and an established geographic availability globally support the growth of this segment.

The single dose segment dominates the format segment in overall GLP-1 analogues industry in 2023.

On the basis of format, the GLP-1 analogues market is segmented into single-dose, multi-dose, and tablets. Single dose accounted for the largest share of the market owing to factors like the ease of administration offered by single dose formulations. Additionally, the availability of the products in autoinjector format further eases the self-administration process. Moreover, single dose format are administered once weekly leading to higher adherence.

North America was the largest market for overall GLP-1 analogues industry in 2023 and also during the forecast period.

Geographically, the GLP-1 analogues market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The market was dominated by North America in 2023 and this dominance is anticipated to continue throughout the forecast period between 2024 and 2032. The market for GLP-1 analogues is expanding in the North America region as a result of factors like availability and access to majority of the GLP-1 analogue products and high demand for these drugs in the region for indications including type 2 diabetes and obesity.

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the GLP-1 analogues market are Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), and AstraZeneca (UK) among others.

Scope of the GLP-1 Analogues Industry

All the market segments have been divided for the GLP-1 Analogues market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Ozempic
• Wegovy
• Rybelsus
• Saxenda
• Victoza
• Trulicity
• Mounjaro
• Zepbound
• Soliqua
• Xultophy
• Bydureon
• Other products

By Format

• Single-dose
• Multi-dose
• Tablets

By Route of Administration

• Subcutaneous
  • Pen injector
  • Autoinjector
• Oral

By Indication

• Diabetes
• Obesity
• Other indications

By End User

• Hospitals and specialty clinics
• Long-term care facilities
• Home care settings

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East
  • GCC
    • Saudi arabia (ksa)
    • United arab emirates (uae)
    • Rest of GCC
  • Rest of Middle East
• Africa

Recent Developments of GLP-1 Analogues Industry:

• In March 2024, the US FDA approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established CVD.
• In November 2023, Eli Lilly and Company (US) received US FDA approval for Zepbound, an obesity treatment that activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst